Dissociation between biochemical and behavioral recovery in MPTP-treated mice.
Injection of a low dose of haloperidol, that has no obvious behavioral effects in normal mice, produces akinesia, catalepsy, and somatosensory neglect in MPTP-treated mice. These neuroleptic-induced sensorimotor impairments are exhibited soon after MPTP treatments and coincide with a decrease in both striatal DA and DOPAC levels. DA and DOPAC content gradually return to near-control levels over a 3-5 month period. Interestingly, while the haloperidol-induced somatosensory deficits declined in parallel with the rise in DA and DOPAC levels, the motor deficits persisted for up to 5 months after MPTP administration. These data suggest subtle differences in the neurochemical mediation of these behaviors and that the persistence of neuronal impairments may not necessarily be revealed by near-normal transmitter levels.
Weihmuller
F B
FB
Department of Psychology, College of Social and Behavioral Sciences, Ohio State University, Columbus 43210.
Hadjiconstantinou
M
M
Bruno
J P
JP
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis*; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D003342:Corpus Striatum / Q000032:analysis* / Q000187:drug effects; D004298:Dopamine / Q000032:analysis*; D018492:Dopamine Antagonists; D004347:Drug Interactions; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D051379:Mice; D010648:Phenylacetates / Q000032:analysis*; D011597:Psychomotor Performance / Q000187:drug effects*; D013469:Sulpiride / Q000494:pharmacology; D013997:Time Factors
D001552:Benzazepines; D018492:Dopamine Antagonists; D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; D013469:Sulpiride; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D006220:Haloperidol; D004298:Dopamine